Search results for "cardiovascular."

showing 10 items of 8644 documents

Ultra-low contrast coronary angiography and zero-contrast percutaneous coronary intervention for prevention of contrast-induced nephropathy: step-by-…

2019

Contrast-induced nephropathy is a serious complication after intravascular administration of iodinated contrast media and is associated with numerous adverse outcomes. Its prevalence is particularly high in patients with multiple comorbidities who undergo coronary angiography and percutaneous coronary intervention (PCI). Currently, the only effective method to prevent contrast-induced kidney injury is adequate hydration and a reduction of contrast volume during the intervention. Recently, new approaches aiming to minimize contrast usage have been proposed, i.e., ultra-low contrast angiography and zero-contrast PCI. However, neither tutorials for these techniques nor reviews of their outcome…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedia_common.quotation_subjectmedicine.medical_treatmentContrast-induced nephropathylcsh:Medicine030204 cardiovascular system & hematologyNephropathyrenal insufficiency03 medical and health sciences0302 clinical medicineIntervention (counseling)medicineContrast (vision)030212 general & internal medicineIntensive care medicinemedia_commonReview Paperbusiness.industrylcsh:RAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseacute kidney injurycontrast-induced nephropathyConventional PCICardiology and Cardiovascular MedicinebusinessComplicationchronic kidney diseaseAdvances in Interventional Cardiology
researchProduct

Zero-contrast percutaneous coronary interventions to preserve kidney function in patients with severe renal impairment and hemodialysis subjects

2019

Introduction Zero-contrast percutaneous coronary intervention (zero-PCI) is a new method for prevention of contrast-induced acute kidney injury (AKI) in patients with chronic kidney disease (CKD). However, evidence for its feasibility, safety and clinical utility is limited to reports of single cases or series of patients. Aim To present outcomes of zero-PCI in patients with severe CKD, including hemodialysis subjects, who were treated with this procedure in order to preserve their renal function. Material and methods Twenty-nine zero-PCIs were performed, mostly as a staged procedure, in 20 patients with advanced CKD. In this group, 4 patients were treated with hemodialysis but presented pr…

medicine.medical_specialtyzero-contrast percutaneous coronary interventionmedicine.medical_treatmentContrast-induced nephropathylcsh:MedicineRenal function030204 cardiovascular system & hematologyRevascularizationurologic and male genital diseasesrenal insufficiency03 medical and health sciences0302 clinical medicine0502 economics and businessmedicineRenal replacement therapyOriginal Paperbusiness.industrylcsh:R05 social sciencesAcute kidney injuryPercutaneous coronary interventionmedicine.diseaseSurgeryacute kidney injurycontrast-induced nephropathy050211 marketingHemodialysisCardiology and Cardiovascular MedicinebusinessKidney diseasePostępy w Kardiologii Interwencyjnej = Advances in Interventional Cardiology
researchProduct

Cohort profile: Thrombolysis in Ischemic Stroke Patients (TRISP): a multicentre research collaboration

2018

PurposeThe ThRombolysis in Ischemic Stroke Patients (TRISP) collaboration aims to address clinically relevant questions about safety and outcomes of intravenous thrombolysis (IVT) and endovascular thrombectomy. The findings can provide observational information on treatment of patients derived from everyday clinical practice.ParticipantsTRISP is an open, investigator-driven collaborative research initiative of European stroke centres with expertise in treatment with revascularisation therapies and maintenance of hospital-based registries. All participating centres made a commitment to prospectively collect data on consecutive patients with stroke treated with IVT using standardised definiti…

medicine.medical_treatment2700 General Medicineregistry030204 cardiovascular system & hematologyRECOMMENDATIONS3124 Neurology and psychiatryBrain Ischemia0302 clinical medicineMedicineProspective StudiesRegistries10064 Neuroscience Center ZurichProspective cohort studyIntersectoral CollaborationThrombectomyRISKEndovascular ProceduresThrombolysisGeneral Medicine3. Good healthStrokeCohortrevascularizationAdministration IntravenousINTRAVENOUS THROMBOLYSISthrombolysismedicine.medical_specialtyMEDLINE610 Medicine & healthRevascularizationfunctional outcome; registry; revascularization; stroke; thrombectomy; thrombolysisCLASSIFICATIONfunctional outcomePOOLED ANALYSIS03 medical and health sciencesALTEPLASEFibrinolytic AgentsHumansMETAANALYSISbusiness.industryStatin treatment10040 Clinic for NeurologyIV THROMBOLYSISSYMPTOMATIC INTRACEREBRAL HEMORRHAGE3121 General medicine internal medicine and other clinical medicineIschemic strokeEmergency medicine570 Life sciences; biologyObservational studybusiness030217 neurology & neurosurgeryBMJ open
researchProduct

Immunoglobulin E (IgE) and ischemic heart disease. Which came first, the chicken or the egg?

2014

Several lines of evidence demonstrate that the immune system plays a pivotal role in development and progression of ischemic heart disease (IHD). More recently, a series of biological and clinical investigations has generated new interest about the existence of a relationship between a specific class of immunoglobulin, that is immunoglobulin E (IgE), and IHD. Data obtained in several epidemiological studies have convincingly demonstrated that the concentration of total serum IgEs is significantly increased in patients with IHD and often correlates with the prognosis. The putative mechanisms are essentially mediated by a physiological interaction between IgEs and mast cells, which triggers t…

medicine.medical_treatmentCoronary Vessel AnomaliesMyocardial IschemiaDiseaseImmunoglobulin Eimmunoglobulin EPathogenesisImmune systemMedicineHumanscardiovascular diseasesMyocardial infarctionMast Cellsischemic heart disease; immunoglobulin E; immune systembiologybusiness.industryGeneral MedicineImmunotherapymedicine.diseaseischemic heart diseaseIncreased IgE levelimmune systemImmunologybiology.proteinAntibodybusinessJob Syndrome
researchProduct

Marsupialization of a large dentigerous cyst in the mandible with orthodontic extrusion of three impacted teeth. A case report

2017

The dentigerous cyst (DC) is the most common type of developmental odontogenic cyst. It is usually asymptomatic and associated with the crown of an unerupted or impacted tooth. However, after a long duration, it is likely to cause significant bone resorption, cortical expansion, and tooth displacement. This report presents a large infected DC in the mandible of a 12-year-old female patient. The DC was located inferior to badly decayed primary molars and surrounded three impacted permanent teeth: canine, first premolar, which had a dilacerated root, and second premolar. The DC was treated successfully by marsupialization and extrusion of the impacted teeth. In conclusion, the combination of …

medicine.medical_treatmentDentistryCase Report030204 cardiovascular system & hematology03 medical and health sciences0302 clinical medicineOdontogenic cyststomatognathic systemmedicinePremolarOrthodontic ExtrusionGeneral DentistryPermanent teethOrthodonticsbusiness.industryImpacted toothMandible030206 dentistrymedicine.diseaseMarsupialization:CIENCIAS MÉDICAS [UNESCO]Dentigerous cyststomatognathic diseasesmedicine.anatomical_structureUNESCO::CIENCIAS MÉDICASOral Surgerybusiness
researchProduct

Managing Peripheral Artery Disease in Diabetic Patients: A Questionnaire Survey from Vascular Centers of the Mediterranean Federation for the Advanci…

2020

Background The Mediterranean Federation for the Advancing of Vascular Surgery (MeFAVS) was founded on October 1, 2018, to enhance cooperation among vascular professionals within Mediterranean countries. Due to its prominent social and economic impact on national health systems, diabetic arteriopathy has been selected as the very first topic to be investigated by the federation. Methods MeFAVS members were asked to reply to a questionnaire on the management of diabetic ischemic foot. Results were collected and analyzed statistically. The questionnaire consisted of 15 multiple choice answers regarding diabetic foot (DF) diagnosis and treatment. The questionnaire was submitted to 21 centers on…

medicine.medical_treatmentPsychological intervention030204 cardiovascular system & hematologyvascular surgerySettore MED/22 - Chirurgia Vascolare030218 nuclear medicine & medical imagingWound care0302 clinical medicineIschemiaPractice Patterns Physicians'Response rate (survey)Practice Patterns Nurses'diabetesMediterranean RegionEndovascular Proceduresvascular medicineGeneral MedicineTreatment OutcomeCardiology and Cardiovascular MedicineVascular Surgical Proceduresdiabetic footmanagementSpecializationReoperationmedicine.medical_specialtyRevascularizationNurse's RoleAmputation Surgical03 medical and health sciencesperipheral arterial diseaseMediterranean Seamedicineperipheral arterial disease; diabetes; vascular medicine; vascular surgeryHumansTrainingHealthcare DisparitiesEndovascular Surgery; Mediterranean Sea; Training; Vascular SurgeryPhysician's RolePatient Care TeamWound Healingbusiness.industryGeneral surgeryVascular surgerymedicine.diseaseDiabetic footAmputationHealth Care SurveysOrthopedic surgeryEndovascular SurgerySurgerybusinesswound careAnnals of Vascular Surgery
researchProduct

Is COVID‐19 infection more severe in kidney transplant recipients?

2021

International audience; There are no studies which have compared the risk of severe Covid-19 and related mortality between transplant recipients and non-transplant patients. We enrolled two groups of patients hospitalized for Covid-19, i.e., kidney transplant recipients from the French Registry of Solid Organ Transplant (n=306) and a single-center cohort of non-transplant patients (n=795). An analysis was performed among subgroups matched for age and risk factors for severe Covid-19 or mortality. Severe Covid-19 was defined as admission (or transfer) to an intensive care unit, need for mechanical ventilation, or death.Transplant recipients were younger and had more comorbidities compared to…

medicine.medical_treatment[SDV]Life Sciences [q-bio]MESH: Registries*AucunMESH: Comorbidity030230 surgerylaw.inventionchemistry.chemical_compound0302 clinical medicinelawcardiovascular diseaseMESH: Risk Factors[SDV.MHEP.MI]Life Sciences [q-bio]/Human health and pathology/Infectious diseasesclinical research / practiceImmunology and AllergyCumulative incidencePharmacology (medical)kidney transplantation / nephrologyMESH: IncidenceMESH: AgedUnivariate analysisMESH: France / epidemiologyMESH: Middle AgedMESH: Transplant Recipients / statistics & numerical data*Acute kidney injuryIntensive care unit3. Good healthMESH: COVID-19 / epidemiologyCohort[SDV.MHEP.MI] Life Sciences [q-bio]/Human health and pathology/Infectious diseasesglomerular filtration rate (GFR)kidney failure / injurymedicine.medical_specialtyinfection and infectious agents - viralinfectious diseaseBrief CommunicationMESH: Graft Rejection / prevention & control03 medical and health sciencesInternal medicineDiabetes mellitusMESH: Severity of Illness IndexMESH: COVID-19 / diagnosis*medicineHumansMESH: SARS-CoV-2Mechanical ventilationCreatinineTransplantationMESH: Humansbusiness.industrySARS-CoV-2MESH: Graft Rejection / epidemiology*COVID-19MESH: Retrospective Studiesmedicine.diseaseKidney TransplantationTransplant RecipientsMESH: Maleimmunosuppressive regimensMESH: Immunosuppressive Agents / therapeutic useMESH: Pandemics*MESH: Propensity Score*chemistryReinfectionMESH: Immunosuppression / methodsMESH: Intensive Care UnitsbusinessMESH: FemaleMESH: Kidney Transplantation*
researchProduct

Evaluation of the Oxiris Membrane in Cardiogenic Shock Requiring Extracorporeal Membrane Oxygenation Support: Study Protocol for a Single Center, Sin…

2021

Background: Veno-arterial extracorporeal membrane oxygenation (VA-ECMO) is the rescue treatment proposed to patients with refractory cardiogenic shock. The VA-ECMO implantation promotes inflammation and ischemia-reperfusion injuries through the VA-ECMO flow, causing digestive mucosa barrier disrupture and inducing translocation of bacterial wall components—Lipopolysaccharides (LPS) with further inflammation and circulatory impairment. LPS is a well-studied surrogate indicator of bacterial translocation. Oxiris membrane is a promising and well-tolerated device that can specifically remove LPS. The main study aim is to compare the LPS elimination capacity of Oxiris membrane vs. a non-absorban…

medicine.medical_treatmentcontinuous renal replacement therapyheart failureoxirisContext (language use)InflammationCardiovascular Medicineartificial membranelaw.inventionStudy ProtocolRandomized controlled triallawmedicineClinical endpointExtracorporeal membrane oxygenationDiseases of the circulatory (Cardiovascular) systemRenal replacement therapycytokines/bloodbusiness.industryCardiogenic shockcardiogenic shockextracorporeal membrane oxygenationmedicine.diseasesurgical procedures operativeendotoxin/bloodRC666-701AnesthesiaHeart failuremedicine.symptomCardiology and Cardiovascular MedicinebusinessFrontiers in Cardiovascular Medicine
researchProduct

Intrahematomal Ultrasound Enhances RtPA-Fibrinolysis in a Porcine Model of Intracerebral Hemorrhage

2021

Catheter-based ultrasound-thrombolysis has been successfully used in a small clinical trial in order to enhance recombinant tissue plasminogen activator (rtPA)-fibrinolysis, for the treatment of spontaneous intracerebral hemorrhages (ICHs). The aim of this study was to investigate the ultra-early effects of ultrasound on hematoma and the surrounding brain tissue in a porcine ICH-model. To achieve this, 21 pigs with a right frontal ICH were randomly assigned to four groups: (1) drainage (n = 3), (2) drainage + rtPA (n = 6), (3) drainage + ultrasound (n = 6), and (4) drainage + ultrasound + rtPA (n = 6). The hematoma volume assessment was performed using cranial MRI before and after the treat…

medicine.medical_treatmentlcsh:Medicine030204 cardiovascular system & hematologyArticle03 medical and health sciences0302 clinical medicineHematomaEdemartPA-fibrinolysisFibrinolysismedicineminimally invasive therapycardiovascular diseasesIntracerebral hemorrhagebusiness.industryUltrasoundlcsh:RGeneral Medicinemedicine.diseaseintracerebral hemorrhageCatheterImmunohistochemistrymedicine.symptombusinessNuclear medicinePerfusion030217 neurology & neurosurgeryultrasound-thrombolysisJournal of Clinical Medicine
researchProduct

Pharmacokinetics of new oral anticoagulants: implications for use in routine care

2018

Introduction: Since 2008, new oral anticoagulants (NOACs) have been approved for the prevention of venous thromboembolism (VTE) in patients receiving hip or knee replacement surgery, prevention of stroke and systemic embolism in patients with non-valvular atrial fibrillation (NVAF), treatment of deep vein thrombosis (DVT), and pulmonary embolism (PE). Premarketing randomized clinical trials (RCTs) of NOACs demonstrated their non-inferiority in terms of efficacy vs. warfarin (traditional oral anticoagulant–TOA), with lower risk of serious adverse drug reactions, especially cerebral hemorrhages. In clinical practice, pharmacokinetic aspects of NOACs have to be carefully taken into account to …

medicine.medical_treatmentnew oral anticoagulantsAdministration OralKnee replacement030204 cardiovascular system & hematologyToxicologyAdherence Bleeding Interactions New oral anticoagulants Over- and under-dosage Persistence Pharmacokinetics Real World Evidence0302 clinical medicineAtrial Fibrillationover- and underdosage030212 general & internal medicinepharmacokineticStrokeRoutine careRandomized Controlled Trials as Topicnew oral anticoagulantAtrial fibrillationpersistenceVenous ThromboembolismGeneral MedicinePulmonary embolismStrokepharmacokineticsHumanmusculoskeletal diseasesmedicine.medical_specialtyinteractionHemorrhageMedication Adherence03 medical and health sciencesPharmacokineticsmedicineHumansReal World EvidenceIn patientOver- and under-dosagecardiovascular diseasesreal-world evidenceIntensive care medicineAgedPharmacologybusiness.industryAnticoagulantAnticoagulantsinteractionsbleedingmedicine.diseaseAdherencePulmonary EmbolismbusinessVenous thromboembolismExpert Opinion on Drug Metabolism & Toxicology
researchProduct